Interestingly, a treatment with dapagliflozin, a medicine for type 2 diabetes, increased the ubiquitination of Notch-ICD, suggesting that dapagliflozin may be an inhibitor of OTUD1, since it impaired the production of IFNγ and IL-2 in CD4+ T cells, prolonged the survival of aGVHD mice, and attenuated the pathogenesis of the targeted organs. The gene discussed is OTUD1; the disease is type 2 diabetes mellitus.